Hero

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

1

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Annual General Meeting of 6 May 2019

2

Annual General Meeting of 6 May 2019

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

3

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st World GI Congress

Celyad Announces April 2019 Investor Conference Schedule

Celyad Announces April 2019 Investor Conference Schedule

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

Celyad Reports Business Update and Full Year 2018 Financial and Operating Results

Discover all news

Carousel

Social Feed

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st… https://t.co/XagBAQ5ro6

1 day ago

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st… https://t.co/XagBAQ5ro6

Le journal des biotechs : Genfit, Nanobiotix, Poxel, entretien avec @ChristianHomsy , @CelyadSA $CYAD https://t.co/hcSowGBaSc

1 day ago

Le journal des biotechs : Genfit, Nanobiotix, Poxel, entretien avec @ChristianHomsy , @CelyadSA $CYAD https://t.co/hcSowGBaSc

RT @LaBourseEtLaVie: Christian Homsy, le Fondateur de @CelyadSA est l'invité de @DidierTestot sur @LaBourseEtLaVie après sa décision de pre…

1 day ago

RT @LaBourseEtLaVie: Christian Homsy, le Fondateur de @CelyadSA est l'invité de @DidierTestot sur @LaBourseEtLaVie après sa décision de pre…

RT @ChristianHomsy: BioCentury - Second shot for shRNA https://t.co/g6GsZy4kmt

1 week ago

RT @ChristianHomsy: BioCentury - Second shot for shRNA https://t.co/g6GsZy4kmt

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st… https://t.co/XagBAQ5ro6

1 day ago

Celyad to Present Update on allogeneic and autologous NKG2D-based CAR-T Candidates in Refractory mCRC at ESMO 21st… https://t.co/XagBAQ5ro6

Le journal des biotechs : Genfit, Nanobiotix, Poxel, entretien avec @ChristianHomsy , @CelyadSA $CYAD https://t.co/hcSowGBaSc

1 day ago

Le journal des biotechs : Genfit, Nanobiotix, Poxel, entretien avec @ChristianHomsy , @CelyadSA $CYAD https://t.co/hcSowGBaSc

RT @LaBourseEtLaVie: Christian Homsy, le Fondateur de @CelyadSA est l'invité de @DidierTestot sur @LaBourseEtLaVie après sa décision de pre…

1 day ago

RT @LaBourseEtLaVie: Christian Homsy, le Fondateur de @CelyadSA est l'invité de @DidierTestot sur @LaBourseEtLaVie après sa décision de pre…

RT @ChristianHomsy: BioCentury - Second shot for shRNA https://t.co/g6GsZy4kmt

1 week ago

RT @ChristianHomsy: BioCentury - Second shot for shRNA https://t.co/g6GsZy4kmt